How the first drug that can “reprogram” the pancreas in type 2 diabetes works
Current treatment regimens for type 2 diabetes in most cases are aimed at reducing sugar. This helps to control the condition, but does not solve the root cause — a violation of the mechanism that should control glucose levels. Dorzagliatin (Dorzagliatin) is the first drug of the GKA class (glucokinase activator), whose task is not […]
Dorzagliatin for renal failure
Safety of Dorzagliatin in renal failure Efficacy and effect on renal function Practical application For doctors For patients Dorzagliatin as a choice for diabetes and kidney failure This makes it a promising choice both for starting therapy and at stages when other drugs are no longer possible due to limitations in renal function. For the […]
Dorzagliatin and restoration of beta-cell function: confirmed data and future studies in type 1 diabetes
Dorzagliatin is an original oral glucokinase activator developed by Hua Medicine specifically for the treatment of type 2 diabetes. In clinical studies, the drug not only showed a significant reduction in blood glucose levels, but also contributed to the improvement of beta-cell function, which makes it particularly valuable in long-term disease management. Confirmed effect on […]
Dorzagliatin: dosage and mode of administration
Dorzagliatin is a modern hypoglycemic drug developed for the treatment of type 2 diabetes mellitus. Its uniqueness lies in the double activation of glucokinase, a key enzyme in the regulation of glucose levels. To get the maximum benefit from therapy, it is important to strictly follow the recommended dosage and intake regimen. In this article, […]
Hua Medicine and Dorzagliatin: a scientific innovation that changed the approach to diabetes treatment
Hua Medicine is a new generation Chinese biopharmaceutical company focused on developing original therapeutic solutions for the treatment of chronic metabolic diseases. Founded in 2011 in Shanghai, the company has established itself as a leader in scientific innovation, combining cutting-edge global technology with a deep understanding of the needs of the Asian and global healthcare […]
Dorzagliatin: sustained glycemic control for 24 and 52 weeks of therapy
Current treatment of type 2 diabetes requires not only rapid reduction of glucose levels, but also long-term stability, restoration of beta-cell function and minimization of risks. In this context, Dorzagliatin — a first — in-class dual glucokinase activator, has shown impressive results in both short-and long-term therapy. Data from 24-and 52-week studies allow us to […]
Dorzagliatin: everything you need to know about the drug for the treatment of type 2 diabetes
Dorzagliatin (trade name-HuaTanNin®) is an innovative drug that has opened a new page in the treatment of type 2 diabetes. It has a unique mechanism of action, aimed not only at reducing blood sugar, but also at restoring the disturbed mechanisms of glucose metabolism. This makes it an important element in modern therapy strategies. How […]
Dorzagliatin in combination therapy
Current understanding of the pathogenesis of type 2 diabetes mellitus (T2DM) requires moving away from monotherapy as a universal approach. The progressive deterioration of beta-cell function, the growth of insulin resistance, and the difficulty of compensating for glycemia dictate the need for combination therapy — with drugs that affect different mechanisms of blood sugar regulation. […]
Hua Medicine and Bayer: strategic partnership in the treatment of type 2 diabetes
In 2020 , Hua Medicine and Bayer announced a strategic partnership and commercial agreement aimed at bringing the innovative drug Dorzagliatin, a first— in-class dual glucokinase activator, to the Chinese market. This agreement is an important step not only for the participants in the deal, but also for the entire healthcare system in China, where […]
Dorzagliatin-an innovative drug for the treatment of diabetes mellitus
Dorzagliatin is an innovative treatment for type 2 diabetes. Thisis the first drug from the group of glucokinase activators that cansimultaneously affect two key metabolic links: pancreatic beta cellsand liver.The drug is aimed at restoring the natural mechanism of regulationof glucose levels. It doesn’t just lower blood sugar, but helps the organs involved incontrolling it […]
